Function
While Dulaglutide is a once-weekly GLP-1RA for type 2 diabetes that lowers HbA1c and body weight by enhancing glucose-dependent insulin secretion and reducing appetite6668, Tirzepatide is approved for type 2 diabetes and obesity, producing larger HbA1c and body-weight reductions than semaglutide in head-to-head trials24.
Mechanism
While Dulaglutide works as a recombinant fusion protein consisting of two disulfide-linked GLP-1(7–37) analogs each covalently fused via a linker to an IgG4 Fc fragment, yielding a large, long-acting GLP-1 receptor agonist protected from DPP-4 degradation66, Tirzepatide is a 39-amino-acid synthetic peptide primarily based on GIP sequence with C20 fatty diacid conjugation that acts as a dual agonist at GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite24.